Navigation Links
Vermillion Announces Appointment of John Hamilton to Board of Directors
Date:4/10/2008

FREMONT, Calif., April 10 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced the appointment of John F. Hamilton to its board of directors. Mr. Hamilton is the former vice president and chief financial officer of Depomed, Inc., a specialty pharmaceutical company.

"John brings more than 20 years of active board-level engagement on financial, strategic and audit matters to Vermillion. His solid experience working with small to mid-size companies in the healthcare sector is a perfect fit with our business model," said Gail Page, President and CEO of Vermillion. "We are pleased to welcome John to the board, especially at such an exciting time in the company's evolution as we prepare to commercialize several of our diagnostic tests later this year. His financial savvy and analytical approach will prove invaluable to the Company."

Mr. Hamilton began his career in the banking industry and went on to hold senior financial positions at several biopharmaceutical companies including Glyko, Inc. -- now BioMarin Pharmaceuticals -- and Chiron Corporation. He sits on the regional board of directors of the Association of Bioscience Financial Officers and is past-president of the Treasurers Club of San Francisco. Mr. Hamilton received his M.B.A. from the University of Chicago and his B.A. in International Relations from the University of Pennsylvania.

Mr. Hamilton's appointment to Vermillion's board of directors went into effect on April 9, 2008. Additionally, Mr. Hamilton will serve as chairman of the Company's audit committee. He will replace Judy Bruner, executive vice president of administration and chief financial officer of SanDisk Corporation, who resigned from the board
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
2. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
3. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
4. Vermillion Announces Effectiveness of Reverse Stock Split
5. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
8. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
9. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
10. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
11. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
(Date:7/30/2015)... 2015 Ascendis Pharma A/S (Nasdaq: ... innovative TransCon technology to address significant unmet medical ... six-month Phase 2 study to evaluate the safety ... 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, ... with the top-line results from our Phase 2 ...
(Date:7/29/2015)... , July 30, 2015 ... results for the second quarter of 2015. CEO ... results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered ... results - Performance drivers ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... be the liaison between United States plasma and fusion science ... of ITER , an international fusion experiment that eventually ... source. , ,On May 24, the seven international ITER participants ... Department of Energy and its ITER Project Office ...
... Madison, Wis. - The parent company of a ... the voluntary nature of the product following the signing ... from requiring them to be implanted. , ,Scott Silverman, ... VeriChip Corp., said the company's practices are consistent with ...
... MINNEAPOLIS - I recently interviewed Robert M. Price about ... Managing the Creative Enterprise". This column includes his comments ... , ,"At its most basic level," he writes, "business ... people orientation is evident as he led Control Data ...
Cached Biology Technology:UW-Madison professor to coordinate U.S. fusion science effort 2Company defends RFID implant product 2New book from former CDC CEO walks readers through innovation 2New book from former CDC CEO walks readers through innovation 3New book from former CDC CEO walks readers through innovation 4
(Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
(Date:6/30/2015)... Pa. , June 30, 2015 ... the company as CEO to help further develop Genisphere,s ... wealth of partnering experience, having spent much of the ... including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. ... focus on Technology and Biotech Corporate Finance. He graduated ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... In an advance toward solving a 50-year-old mystery, scientists ... drinking water, toothpastes, mouth rinses and other oral-care products ... journal Langumir . Karin Jacobs and colleagues ... still exists over exactly how fluoride compounds reduce the ...
... 2013   Exemplar LIMS™  has been selected as the lab ... Sinai Medical Center in New York . ... (NGS) platform workflows from request through secondary analysis. ... laboratory, and Exemplar LIMS is used to perform the detailed ...
... ends while their leaves are more pointed? In a new ... PLOS Biology , scientists from the John Innes Centre and ... petals is controlled by a hidden map located within the ... functions related to their shape. Leaves acquire sugars for a ...
Cached Biology News:Mount Sinai Selects Exemplar LIMS for Genomics Core Facility 2How petals get their shape 2
Practical tool for easy, effective sealing of 0.2ml PCR tubes and plates using cap strips....
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Time- and temperature-controlled microwave ... Rehydration and Antigen Retrieval of ... offers ease of use, high ... and high performance. When used ...
... discovery system miniaturizes, integrates and automates ... LabChip technology, the LabChip 3000 performs ... flow fashion. LabChip assays are separations-based, ... what is achievable in homogenous, well-based ...
Biology Products: